Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (August 2021)
15 slides from Harrow's investor presentation, August 2021
Slide 1: Corporate Presentation | August 2021
Corporate Presentation | August 2021 1
Slide 2: Safe Harbor
Safe Harbor This presentation contains express “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying a
Slide 3: Harrow Health, Inc.
Harrow Health, Inc. ➢ Harrow is a growing leader in the U.S. ophthalmic healthcare market. ➢ Harrow has built a strong market position by selling high-value ophthalmic drugs to institutions, which now includes over 10,000 doctors, hospitals and ASCs. ➢ Our growth strategy is to expand our current re
Slide 4: Traditional Pharmaceutical Value Chain
Traditional Pharmaceutical Value Chain ➢ Layers of middle-men thrive. ➢ “Tiered” formularies and layers of intermediaries “feed” an opaque system. ➢ “Discount cards” and “access” programs try to soften consumer costs and confusion. ➢ Prescribers and consumers view pharmaceuticals and pharmacy as a p
Slide 5: Harrow's Simple Approach
Harrow’s Simple Approach - ➢ Cash-pay focused. ➢ No pharmacy benefit managers (PBMs), wholesalers or distribution “middlemen.” ➢ No prior authorizations, formulary rejections, rebates, or discount cards. ➢ We make pharmaceuticals and pharmacy simple and transparent. 5
Slide 6: ImprimisRx
ImprimisRx ➢ The leading FDA-registered cGMP ophthalmic pharmaceutical drug compounder. ➢ Fully-integrated national sales and customer service teams, and an efficient, scalable, and tech-enabled national distribution platform. ➢ Ophthalmic surgical and chronic eyecare markets are large and growing:
Slide 7: AMP-100 (Ocular Surface Anesthesia)
AMP-100 (Ocular Surface Anesthesia) ➢ Clinical and pre-clinical studies for AMP-100, a patented non-opioid ophthalmic surgical drug candidate, demonstrated: ➢ Safety, with most common side effect being mydriasis (pupil dilation), which most ophthalmologists consider beneficial; ➢ Clinical effect is
Slide 8: Harrow Health Innovation Pipeline
Harrow Health Innovation Pipeline* ➢ By partnering with doctors, Harrow has developed compounded products to address unmet patient needs, both large and small, helping eyecare professionals take care of their patients. R&D Pre- Stability Clinical Commercial Formulation Studies Evaluation Launch 050-
Slide 9: Visionology
Visionology ➢ Direct-to-consumer eyecare subsidiary of Harrow founded in 2020. ➢ Focused on helping patients manage chronic eye disease using a simple and seamless user experience that was designed after 1,200 consumer interviews. ➢ Launched regionally in May 2021. ➢ Leverages our Eyecare-as-a-Servi
Slide 10: Revenues, Gross Margin and Assets
Revenues, Gross Margin and Assets (Revenues and Assets in Thousands) $106,966 75.6% 70.4% 67.3% 60.1% 50.7% 49.6% 46.4% $59,085 $57,474 $51,165 $49,451 $48,871 34.2% $41,372 $33,600 Record $27,247 $26,774 $23,917 $19,942 $14,131 $10,242 $9,716 $1,660 2014 2015 2016 2017 2018 2019 2020 1H 2021 Consol
Slide 11: Demonstrating Financial Escape Velocity
Demonstrating Financial Escape Velocity (Dollars in Thousands) 645% … As the business generates more revenue, with marginal increases in operating expenses, more of the incremental revenue dollars have become profit. $10,000 $5,700 $4,600 $200 199% 130% $(7,500) $(7,000) 73% 77% 70% 54% $(10,000) $(
Slide 12: COVID-19 Recovery
COVID-19 Recovery (Quarterly Revenues and Adjusted E(L)BITDA in Thousands) $18,100 $15,400 $14,400 $14,600 Mandated limitations on elective surgeries $8,100 $5,700 $4,300 $4,000 $3,000 2Q20 3Q20 4Q20 1Q21 2Q21 $(1,700) Consolidated Revenues Adjusted E(L)BITDA 12
Slide 13: Harrow Health Drug Candidate Royalty Pipeline
Harrow Health Drug Candidate Royalty Pipeline ➢ Harrow Health owns royalty rights on out-licensed drug candidates in clinical development at both Surface Ophthalmics (4% royalty) and Melt Pharmaceuticals (5% royalty). ➢ The markets for Surface’s and Melt’s drug candidates are in the billions of doll
Slide 14: Harrow Health, Inc.
Harrow Health, Inc. ➢ Positioned to be a high growth eyecare-focused healthcare company. ➢ Revenues expected to exceed $100M within the next few years, and to accelerate through the acquisition of high-value products. ➢ Expense discipline captures significant income on incremental revenue growth. ➢
Slide 15: 102 Woodmont Blvd., Ste 610 Nashville, Tennessee 37205
102 Woodmont Blvd., Ste 610 Nashville, Tennessee 37205 www.HarrowInc.com Jamie Webb Director of Communications and Investor Relations jwebb@harrowinc.com Direct: 615-733-4737 15